THE OTHER HUMAN FACE OF BIOTECHNOLOGY

Anticipating Biotechnology’s Success in Developing Effective New Medications

Testimony of

Alan Sager, Ph.D.
Professor,
Boston University School of Public Health
715 Albany Street
Boston, Massachusetts 02118

phone (617) 638-4664
fax (617) 638-5374
asager@bu.edu

Written Version of Testimony before the Joint Economic Committee,
United States Congress

Biotech Summit: Putting a Human Face on Biotechnology
Room 216,
Hart Senate Office Building

10:00 A.M.,
Wednesday 29 September 1999

Disclaimer: As always, I write and speak only for myself, not on behalf of Boston University or any of its components.

Acknowledgment: This testimony rests heavily on analyses conducted with my colleague, Deborah Socolar.
Mr. Chairman and members of the Committee—

Good afternoon.

My name is Alan Sager and I am a professor at the Boston University School of Public Health. I am honored to be here.

You have heard great things today. Many wonderful new medications may be marketed soon.

But biotech has a second human face—the face of people who cannot afford today’s medications and will not be able to afford tomorrow’s. I would like to address the problems of:

- making all needed medications affordable for all Americans, while
- building a durable financial foundation under drug research and delivery in the U.S.

I am absolutely convinced we can do both of these. But not by continuing business as usual.

**What is the nature of the problem?**

Many Americans can’t afford needed prescription drugs because they lack insurance, suffer low incomes, and can’t afford high American prices.

Today, 70 million Americans of all ages have no insurance for prescription drugs. Additional millions have skimpy coverage. Yet American prescription drug spending per person this year will be the world’s highest. And total prescription drug spending will be close to $120 billion this year, or about ten percent of overall U.S. health spending.

Worse, people without insurance typically pay the world’s highest prices for prescription drugs. That’s because average American prices are highest in the world, and uninsured Americans pay prices above the average.

So it is not surprising that 17 percent of all Americans—and 42 percent of uninsured Americans—reported not filling prescriptions for financial reasons,\(^1\)

And these are the economy’s fat years, to paraphrase what Joseph told Pharaoh.

The drug cost problem will probably worsen. Drug spending in the U.S. has been rising about three times as fast as overall health care spending.

Today, some 300 new biotech medicines are reported to be in the pipeline, along with some 1,000 new drugs in the overall pharmaceutical pipeline.\(^2\)

If too few of these medications work, we will have a lot of disappointed investors.

But what if a great number of them do work?
Then, many more patients will have to choose between their money and their lives. And still other patients will not even have this choice, because they will lack the money.

Will medical miracles be affordable for all or merely profitable for some?

If we fail to make vital drugs available to all who need them, how great will be the public fear and anger? Reasonable action today will prevent over-reaction tomorrow.

Together, we face three choices:

- Many of us could suffer and die for lack of needed medications, but that is intolerable.
- We could spend more public or private money—or both—to buy needed drugs, but that is both unaffordable and unnecessary.
- We could secure more drugs from manufacturers for the amount we already spend.

What are the causes of the problem of unaffordable medications?

To make sense these problems and to devise solutions to protect the biotechnology industry specifically, we must examine the prescription drug industry generally.

1. High U.S. drug prices make drug insurance unaffordable for many.

2. U.S. prices are high mainly because, alone in the world, our government does not protect us from the world’s drug makers. This year, Americans paid at least $16.2 billion extra for drugs. This is an invisible subsidy to other rich nations—the world’s least-well-targeted foreign aid.

3. The drug makers paralyze government action by claiming

   - that today’s prices and profits are legitimate products of a free market;
   - that high U.S. prices and profits are needed to finance vital research; and
   - that even moderate restraint on prices or profits will collapse the drug makers’ fragile financial house of cards.

These three claims are false. The drug makers’ prices and profits can’t be sustained at current or hoped-for levels. During the 1990s, the nation’s big drug makers’ returns on equity were two and one-quarter times the average for all U.S. industries. It is unrealistic to expect that American patients can or will continue to pay prices high enough to sustain these profits.

Returns this high are not justified by legitimate market forces. Sadly, few signs of a living free market can be detected in the drug industry—outside the retail pharmacy
sector. (The evidence for this position is detailed in the July 1999 report to the U.S. House of Representatives Prescription Drug Task Force that I co-authored with my colleague, Deborah Socolar.) Without either functioning free markets or effective government action, we have only one thing—anarchy. And anarchy allows the strong to earn unwarranted profits.

That is why PhRMA, the drug makers’ trade association, spreads a fog of fear—PhRMA’s Fog of Fear—to try to paralyze public action and to preserve anarchy.

But the drug makers themselves sometimes pay a price for this anarchy. Some individuals connected with the biotech and prescription drug industries have worried aloud about the instability of biotech stock prices in 1993-1994 and again in recent months. They have condemned legislative efforts to contain prices or improve coverage, claiming that these efforts would impede the flow of capital to the industry. But their position amounts to condemning a symptom. As long as many Americans cannot afford needed medications, we will see repeated attempts to lower prices and improve coverage. The industry cannot wish away this simple reality. Without just and equitable access to medications, there will be no peaceful enjoyment of high drug and biotech stock prices. The challenge is to win both.

4. The United States government rejects PhRMA’s claims emphatically by taking a 40 percent (or so) price discount for medications for the V.A. and military, and by taking a 15 percent (or so) price cut for the Medicaid program. This is what foreign governments have long done for all their citizens.

But unlike governments elsewhere, our government has protected itself alone. In so doing, it leaves the drug makers free to raise prices on the rest of us in order to reach their revenue targets.

Government’s other main role has been in taking the risks to finance much of the basic research foundation on which the biotech industry rests, as many individuals have emphasized.

Sustained high drug prices and profits—in combination with growing numbers of patients suffering for lack of needed medications—could lead an angry future Congress to legislate harsh price and profit controls. These controls could indeed undermine needed research. Moderate action and compromise today will protect both Americans and our vital drug research community tomorrow.

What solutions are possible—to win affordable medications for all Americans?

Some drug makers’ magical solution is to promise that new drugs will reduce costs of hospital and doctor care. That’s easy to promise but hard to deliver, on average. Some short-run savings may be possible in some instances. While preventing or treating one disease is a blessing, doing so will inevitably expose patients to other diseases. This means that any dollar savings are one-time only.
Prudence demands that we plan against the contingency that drug breakthroughs will fuel higher spending.

It is widely recognized that efforts to expand Medicare or other coverage of vulnerable people will be very costly unless they are coupled with price or other spending restraints.

U.S. drug prices and spending per person are already the highest in the world. We already spend enough to buy all the drugs that all Americans require. Therefore, the first challenge is to protect all people without spending more money. The second challenge is to do so in ways that provide fair and adequate financing for new and effective drugs.

Several approaches could be used to meet these challenges. Here are a few:

I. **Internationally**, negotiate a drug price peace treaty. All wealthy nations would agree to pay the same fair prices for prescription drugs, and to subsidize sick people in poor nations. Our government would have to take the lead. This is probably worth doing no matter what domestic approaches are taken.

II. **Domestically**, I see only two alternatives. Either:

A. We could engage in years or decades of increasingly mean-spirited and fragmented fights over drug prices, profits, and coverage. Anger and threats would be the highlights. So would corporate stock price instability.

OR

B. We could sit down to negotiate a comprehensive package deal. By focusing on the two real bottom line issues—affordable medications for all plus fair returns on invested equity, this approach could short-circuit the angry trench warfare fights about the details. The package could include these eight elements:

1. Payors and drug makers negotiate fair returns on drug makers’ equity. This would be the rate adequate to finance needed research and retain needed capital. Adequate overall profits would be combined with generous rewards to those who develop valuable medications.

2. In exchange, drug makers produce and distribute enough medications to fill all prescriptions written by physicians for Americans. Drug makers would find it inexpensive, on average, to provide the increased volumes (higher than today’s production levels) required to protect all Americans. That is because drug makers face high fixed costs for research and setting up manufacturing plants, but extraordinarily low marginal or incremental costs to make additional amounts of most medications.

3. To make the deal real, drug prices would be set to achieve negotiated profit and total revenue targets.

4. To make medications more affordable, drug makers would be encouraged to cut wasteful marketing and advertising costs.
5. Physicians need better evidence on each drug’s benefits and costs. Studies to obtain this information should be financed, compiled, and disseminated by objective parties, not by industry.

6. To encourage better use of medications, patients deserve improved information about proper drug use.

7. To protect patients, pharmacists need to be assured of payments adequate to cover the time of both patient counseling and accurate dispensing.

8. It may also be desirable to target scarce public and private research dollars down paths that are more likely to develop medications that are both effective and affordable for all.

Evidence supporting the findings and conclusions presented in this testimony is found in Alan Sager and Deborah Socolar, Affordable Medications for Americans: Problems, Causes, and Solutions, presented to the Prescription Drug Task Force, United States House of Representatives, 27 July 1999. It is available from www.house.gov/berry/prescriptiondrugs/. Refer to “studies of interest.”

(A summary of that report is incorporated into this testimony; it appears on the following pages.)

Thank you for the opportunity to present these views. I will be happy to respond to your questions, either today or subsequently.

---

NOTES
